Table Graph
      published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsSolaymani-Dodaran, 2021 (REV) 0.82 [0.44; 1.51] 0.82[0.44; 1.51]Solaymani-Dodaran, 2021 (REV)10%373NAnot evaluable clinical improvement (time to event analysis only)detailed resultsSolaymani-Dodaran, 2021 (REV) 1.06 [0.85; 1.33] 1.06[0.85; 1.33]Solaymani-Dodaran, 2021 (REV)10%380NAnot evaluable mechanical ventilationdetailed resultsSolaymani-Dodaran, 2021 (REV) 0.62 [0.32; 1.18] 0.62[0.32; 1.18]Solaymani-Dodaran, 2021 (REV)10%373NAnot evaluable ICU admissiondetailed resultsSolaymani-Dodaran, 2021 (REV) 0.81 [0.46; 1.44] 0.81[0.46; 1.44]Solaymani-Dodaran, 2021 (REV)10%373NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-13 22:47 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 509 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons